Covered recipient · General Payments record
USMAN UMAR
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$684.26
- Reported across 28 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $400.23 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $120.81 | 5 |
| PFIZER INC. | $61.84 | 3 |
| Bayer HealthCare Pharmaceuticals Inc. | $55.82 | 2 |
| Amgen Inc. | $40.47 | 2 |
| Merck Sharp & Dohme Corporation | $39.29 | 2 |
| ABBVIE INC. | $34.88 | 1 |
| Acerta Pharma LLC | $33.65 | 2 |
| Novo Nordisk AS | $13.47 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $34.88 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106259352 | CMS |
| Amgen Inc. | $21.44 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117706318 | CMS |
| Amgen Inc. | $19.03 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116188139 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.54 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104215335 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.11 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104574188 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $26.01 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086156526 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $29.81 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086111946 | CMS |
| Lilly USA, LLC | $26.24 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135439762 | CMS |
| Lilly USA, LLC | $22.30 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135487384 | CMS |
| Lilly USA, LLC | $26.75 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135493092 | CMS |
| Lilly USA, LLC | $24.63 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135472779 | CMS |
| Lilly USA, LLC | $20.89 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135493090 | CMS |
| Merck Sharp & Dohme LLC | $23.20 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141918016 | CMS |
| Merck Sharp & Dohme LLC | $16.09 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141985119 | CMS |
| Novo Nordisk Inc | $13.47 | 08/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096928140 | CMS |
| PFIZER INC. | $17.97 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131697755 | CMS |
| PFIZER INC. | $21.72 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132014170 | CMS |
| PFIZER INC. | $22.15 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131866576 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.